HB-adMSCs is under clinical development by Hope Biosciences and currently in Phase I for Primary Lateral Sclerosis. According to GlobalData, Phase I drugs for Primary Lateral Sclerosis does not have ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS ...

a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS). Under the leadership of Principal Investigator Prof Merit Cudkowicz, MD, Director of the Sean M. Healey ...

During his departure announcement in 2024, Neil thanked his bosses for their patience when he took off “a day or two here and there battling everything from multiple sclerosis and COVID to ...

Microglia, the brain's primary and most prominent immune ... for treating other diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and eye diseases that involve the loss of ...

Many people living with multiple sclerosis (MS) experience speech issues. With MS, you can develop persistent speech difficulties, or you might have speech problems that come and go. You may find ...

New research from Mass General Brigham and Washington University School of Medicine in St. Louis found Xenon gas inhalation reduced neurodegeneration and boosted protection in preclinical models o ...

Microglia, the brain's primary and most prominent immune ... for treating other diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and eye diseases that involve the loss of ...

Microglia, the brain's primary and most prominent immune ... for treating other diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and eye diseases that involve the loss of ...